MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-01-31, ALZN had -$1,736,294 decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,736,294
Unit: Dollar
Positive Cash Flow Breakdown
    • Accounts payable and accrued lia...
    • Depreciation expense
    • Stock-based compensation to empl...
Negative Cash Flow Breakdown
    • Net loss
    • Prepaid expenses and other curre...

Cash Flow
2026-01-31
2025-10-31
2025-07-31
Purchase of equipment
--0
Net cash used in investing activities
--0
Interest expense - debt discount
--0
Net loss
-2,198,991 -1,000,758 -2,702,684
Depreciation expense
27,685 27,685 27,685
Stock-based compensation to employees and consultants
9,300 31,514 42,902
Prepaid expenses and other current assets
714,128 -35,943 79,239
Accounts payable and accrued liabilities
1,139,840 -265,823 348,550
Net cash used in operating activities
-1,736,294 -1,171,439 -2,362,786
Net proceeds from the issuance of preferred stock, net
--4,035,000
Net proceeds from the issuance of preferred stock
0 4,035,000 -
Net cash provided by financing activities
0 0 4,035,000
Net (decrease) increase in cash
-1,736,294 -1,171,439 1,672,214
Cash at beginning of period
4,449,433 3,948,658 -
Cash at end of period
2,713,139 4,449,433 -
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net (decrease)increase in cash-$1,736,294 Accounts payable andaccrued liabilities$1,139,840 Depreciation expense$27,685 Stock-based compensation toemployees and consultants$9,300 Net cash used inoperating activities-$1,736,294 Canceled cashflow$1,176,825 Net loss-$2,198,991 Prepaid expenses andother current assets$714,128

Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro, Inc. (ALZN)